| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
SANUWAVE Health, Inc.
13D/A
SNWV · 80303D305
|
10.8% |
12/15/2025
Event 12/11/2025
|
||||
| Manchester Management Company, LLC | 10.8% | |||||
| Manchester Management PR, LLC | 10.8% | |||||
| Manchester Explorer, L.P. | 10.1% | |||||
| James E. Besser | 10.8% | |||||
| Morgan C. Frank | 10.7% | |||||
|
Modular Medical, Inc.
13D/A
MODD · 60785L108
|
10.5% |
4/7/2025
Event 3/31/2025
|
||||
| Manchester Management Company, LLC | 9.3% | |||||
| Manchester Explorer, L.P. | 8.7% | |||||
| Manchester Management PR, LLC | 9.3% | |||||
| James E. Besser | 10.5% | |||||
| Morgan C. Frank | 9.6% | |||||
| JEB Partners, L.P. | 0.6% | |||||
| Schedule 13G · 3 securities · passive | ||||||
|
Alpha Cognition Inc.
13G
ACOG · 02074J501
|
7.4% |
9/23/2026
Event 7/14/2026
|
||||
| Manchester Management Company, LLC | 6.9% | |||||
| Manchester Management PR, LLC | 6.9% | |||||
| Manchester Explorer, L.P. | 6.1% | |||||
| James E. Besser | 7.4% | |||||
| Morgan C. Frank | 6.3% | |||||
|
Eupraxia Pharmaceuticals Inc.
13G/A
EPRX · 29842P105
|
4.5% |
8/13/2026
Event 6/30/2026
|
||||
| Manchester Management Company, LLC | 4.3% | |||||
| Manchester Management PR, LLC | 4.3% | |||||
| Manchester Explorer, L.P. | 4.1% | |||||
| James E. Besser | 4.5% | |||||
| Morgan C. Frank | 4.3% | |||||
|
Neuroone Medical Technologies Corp
13G/A
NMTC · 64130M209
|
4.9% |
2/14/2025
Event 12/31/2024
|
||||
| Manchester Explorer, L.P. | 4.1% | |||||
| Manchester Management Company, LLC | 4.6% | |||||
| Manchester Management PR, LLC | 4.6% | |||||
| James E. Besser | 4.9% | |||||
| Morgan C. Frank | 4.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.